Zotarolimus
Zotarolimus (INN, codenamed ABT-578) is an immunosuppressant. It is a semi-synthetic derivative of rapamycin. It was designed for use in stents with phosphorylcholine as a carrier. Coronary stents reduce early complications and improve late clinical outcomes in patients needing interventional cardiology. The first human coronary stent implantation was first performed in 1986 by Puel et al. However, there are complications associated with stent use, development of thrombosis which impedes the efficiency of coronary stents, haemorrhagic and restenosis complications are problems associated with stents.
primaryTopic
Zotarolimus
Zotarolimus (INN, codenamed ABT-578) is an immunosuppressant. It is a semi-synthetic derivative of rapamycin. It was designed for use in stents with phosphorylcholine as a carrier. Coronary stents reduce early complications and improve late clinical outcomes in patients needing interventional cardiology. The first human coronary stent implantation was first performed in 1986 by Puel et al. However, there are complications associated with stent use, development of thrombosis which impedes the efficiency of coronary stents, haemorrhagic and restenosis complications are problems associated with stents.
has abstract
Zotarolimus (INN, codenamed AB ...... ndeavor and Resolute products.
@en
ATC prefix
CAS number
221877-54-9
FDA UNII code
H4GXR80IZE
IUPAC name
(3S,6R,7E,9R,10R,12R,14S,15E,1 ...... e-1,5,11,28,29(6H,31H)-pentone
@en
thumbnail
Link from a Wikipage to an external page
Wikipage page ID
17,545,599
Wikipage revision ID
724,622,402
ChEMBL
ChemSpiderID
21,468,821
molecular weight
smiles
StdInChIKey
CGTADGCBEXYWNE-JUKNQOCSSA-N
synonyms
hypernym
comment
Zotarolimus (INN, codenamed AB ...... oblems associated with stents.
@en
label
Zotarolimus
@en